Anfield Capital Management, LLC - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 357 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2022. The put-call ratio across all filers is 0.48 and the average weighting 0.2%.

Quarter-by-quarter ownership
Anfield Capital Management, LLC ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q4 2022$17,753
-60.5%
312
-72.4%
0.01%
-57.1%
Q3 2022$45,000
-6.2%
1,132
+3.6%
0.02%
-4.5%
Q2 2022$48,000
+29.7%
1,093
+16.6%
0.02%
+57.1%
Q1 2022$37,000
+236.4%
937
+250.9%
0.01%
+250.0%
Q4 2021$11,000
+1000.0%
267
+1171.4%
0.00%
Q3 2021$1,000210.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2022
NameSharesValueWeighting ↓
TRAN CAPITAL MANAGEMENT, L.P. 1,084,118$61,686,2857.80%
SNYDER CAPITAL MANAGEMENT L P 3,983,814$226,679,0175.12%
First Light Asset Management, LLC 923,119$52,525,4714.88%
Redwood Investments, LLC 441,809$25,138,9323.37%
BERNZOTT CAPITAL ADVISORS 444,728$25,305,0233.27%
DOHENY ASSET MANAGEMENT /CA 46,050$2,6203.04%
Crawford Lake Capital Management, LLC 42,171$2,399,5302.75%
2Xideas AG 416,586$23,703,7432.51%
Granite Investment Partners, LLC 902,882$51,373,9862.14%
HighMark Wealth Management LLC 41,790$2,377,8511.79%
View complete list of HALOZYME THERAPEUTICS INC shareholders